Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Clin Pharmacol. 2013 Mar;69(3):711-4. doi: 10.1007/s00228-012-1383-6. Epub 2012 Sep 16.

Placebo? no thanks, it might be bad for me!

Author information

  • 1Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy. silvio.garattini@marionegri.it

Abstract

OBJECTIVE:

To assess the potential damage to patients from the inappropriate use of placebo.

METHODS:

Pivotal clinical trials of new drugs were evaluated for the treatment of multiple sclerosis following effective treatment with beta interferons and glatiramer acetate. The differences in the relapse rate between the experimental arms of the trials with interferons and glatiramer and the placebo groups were calculated.

RESULTS:

In ten pivotal trials, 2,752 patients were given placebo instead of the best proven treatments. The annualized relapse rate was reported for 2,405 of these patients. Patients receiving placebo suffered 630 more relapses than those treated with interferons or glatiramer.

CONCLUSIONS:

The inappropriate use of placebo in clinical trials unduly harms patients. The use of standard active comparators would preserve patients' rights and better define the respective clinical value of new medicines.

Comment in

PMID:
22983310
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer
    Loading ...
    Write to the Help Desk